Dr. John Crary’s Neuro Logic

With bold ideas and a pioneering mix of disciplines, a leading New York City neuropathologist is pushing for a radically ambitious project to prevent brain diseases.
Dr. John Crary’s Neuro Logic
Dr. Crary’s “biomechanical cascade hypothesis” posits that variations in one small part of the brain’s anatomy could influence vulnerability to early injury that initiates Alzheimer’s. Photo: Valeria Reverdo

By Amely Greeven

When Mount Sinai neuropathologist Dr. John Crary peers through his microscope at brain tissue donated to the institution’s Neuropathology Brain Bank, he feels like a deep-ocean explorer, privileged to journey around infinitely complex terrain that few people get to see. Examining minute structures in parts of the brain that most have never heard of, Crary, who runs the Crary Lab at the Icahn School of Medicine at Mount Sinai, probes the hidden depths for clues to quandaries that are anything but abstract. What actually drives memory loss and other symptoms of neurodegeneration? Why do some regions of the brain succumb to degenerative diseases as we age, or even before we age, while others don’t? And how can greater understanding help us to slow irreversible memory and cognitive loss, or one day even prevent it happening at all?

“Every brain tells a story,” Crary says, noting that the Brain Bank, which receives brains of deceased individuals from families that he and his team sometimes meets personally, has supported 1,200 projects in other research labs around the world. “Toxic exposure, pesticides, Agent Orange, traumatic brain injury, concussion—by looking through the microscope, and by talking with families, you start to piece together the storyline.” His dedicated sleuthing has inspired unconventional discoveries that more removed scientists, working on theories or guiding drug trials, might not make.

Case in point: Twelve years ago, a treasure trove of forgotten studies hidden in the Brain Bank sparked Crary’s observation that some brains of patients who died with Alzheimer’s contained abnormal tau protein tangles without the amyloid plaques that have long been considered a hallmark of the disease. His research, which identified a distinct condition called primary age-related tauopathy, or PART, led to a paradigm shift in how scientists classify and understand neurodegenerative disease, and helped locate a new target for developing prevention and treatment. (It also helped explain why some older people develop memory difficulties without meeting the biological criteria for Alzheimer’s disease.) Crary describes how this kind of “pure discovery” science, free of commercial incentives, matters deeply—especially in an era when controversy over scientific misconduct and amyloid-targeting drugs, as told in the recent book Doctored by Charles Piller, has damaged trust.

More recently, Crary’s penchant for pushing boundaries through merging the study of tissue-driven “brain stories” with AI, genetics and stem cell-derived brain models took him down another unexpected path. Fascinated by the connection of head trauma and neurodegeneration, and using advanced digital imaging of brains, he worked with a neural imaging engineer named Dr. Frank Provenzano at Columbia University to develop an unconventional theory he calls the “biomechanical cascade hypothesis.” It posits that variations in one small, specific part of the brain’s anatomy—and the subtle mechanical forces this area, a tiny notch in the center of the brain, experiences over a lifetime—could influence vulnerability to early injury that initiates Alzheimer’s. “While it sounds like a big claim, our hypothesis credibly points to something that may actually trigger the cascade of secondary downstream problems we all recognize and try to treat today, like neuro inflammation,” Crary says. He believes that this fresh-eyed approach, while still an unproven theory, brings the field back to the first pillars of scientific research: “It’s about asking, with integrity and truthfulness, what do we actually know about these diseases?” If it holds up, this new theory could reveal all kinds of early interventions to protect vulnerable individuals.

Now, Crary and his lab seek to continue the audacious innovation, with a “moon shot project” directed at identifying the causes of neurodegeneration, once and for all. At the center of the project is a Learning Research Network that Crary proposes building to unite labs, universities and brain banks around the world in a noncommercial network that will digitally map brains down to the individual cell and subcellular level.

This bold mission requires the recruitment of youthful and curious scientists equally driven to explore the next frontier of human knowledge—and of course, funding. “Research needs to prioritize patients over profits if we want to address prevention,” Crary says. It also needs the big-vision believers with the persistence and deep pockets for long-term, culture-changing exploration.

But Crary knows the moon shot, which is worth taking. “This is a legacy project,” he says, noting that it also creates a living legacy for the families that gift brain specimens to the banks. “What better bequest could we leave for our children, and their children, than the freedom from the fear and suffering of neurodegeneration and dementia?” crarylab.org

Explore more in Health at The Purist.

Never miss an issue—join The Purist community.